Home » MAP Pharma’s Asthma Drug Fails Late-Stage Study
MAP Pharma’s Asthma Drug Fails Late-Stage Study
MAP Pharmaceuticals Inc. said its experimental treatment for asthma in children failed a late-stage study, sending its shares crashing 40 percent in after-hours trading.
CNBC
CNBC
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May